Publikationer Magnus Essand

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer:

  1.  Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, Essand M. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death and Disease. 2020, 12(1):48,. DY and ME are shared senior authors.

  2. Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clinical Cancer Research, 2018, 24: 6185-6194.

  3. Lugano R, Vemuri K, Yu D, Bergqvist M, Smits A, Essand M, Johansson S, Dejana E, Dimberg A. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. Journal of Clinical Investigation, 2018, 128: 3280-3297.

  4. Fotaki G, Jin C, Kerzeli IK, Ramachandran M, Martikainen MM, Karlsson-Parra A, Yu D, Essand M. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology. 2017, 7(3):e1397250. DY and ME are shared senior authors.

  5. Ramachandran M, Yu D, Dyczynski M, Baskaran S, Nelander S, Zhang L, Lulla A, Lulla V, Saul S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus. Clinical Cancer Research. 2017, 15: 1519-1530.

  6. Yu D, Leja-Jarblad J, Loskog A, Hellman P, Giandomenico V, Oberg K, Essand M. Preclinical evaluation of AdVince, an oncolytic adenovirus adapted for treatment of liver metastases from neuroendocrine cancer. Neuroendocrinology, 2016, 105: 54-66.
  7.  Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M, Yu D. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Molecular Medicine. 2016, 8: 702-11. ME and DY are shared senior authors.
  8. Ramachandran M, Jin C, Yu D, Eriksson F, Essand M. Vector-encoded Helicobacter pylori neutrophil activating protein promotes maturation of dendritic cells with Th-1 polarization and improved migration. J Immunol, 2014, 193: 2287-2296.
  9. Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes RO, Tazzyman S, Essand M, Morrow FJ, Lewis CE. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Research, 2013, 73: 490-495.
  10. Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. TARP-TCR-engineered T cells specifically kill HLA-A2 positive prostate and breast cancer cells. Proc Natl Acad Sci USA, 2012, 109: 15877-15881.